Malignant tumors of the liver in children
Introduction
Although rare, hepatoblastoma (HB) is the most frequent of the malignant pediatric liver tumors. After neuroblastoma and nephroblastoma, HB is the third most common abdominal solid tumor in very young children. Hepatocellular carcinoma (HCC) is most often seen in older children and adolescents.1 An interesting hybrid tumor, HB with features of HCC variably called transitional or “not-otherwise-specified” (NOS), exists on the age continuum between HB and HCC. In Asia and Africa, hepatocellular carcinoma (HCC) occurs more frequently than HB, which is probably a consequence of the higher prevalence of hepatitis B infection on those continents. Interestingly, the incidence of HCC seems to have decreased in some countries as a consequence of wide spread vaccination programs against hepatitis B infection in these areas.2 In today’s age of electronic communication, the possibility of collaboration on an international scale has increasingly facilitated treatment and research of these rare tumors. For example, in addition to international cooperative research and education services, advice on treatment of difficult cases is now possible with the support of a consultation service which can be accessed under the virtual consultation service tab on the international pediatric liver tumor website (www.siopel.org). This virtual consultation service gives any interested treating clinician, some of whom may see a pediatric liver tumor only once every few years, real time access to expert opinion from an international panel of pediatric liver tumor oncologists, pathologists, radiologists, and surgeons.
Section snippets
Hepatoblastoma (HB)
The treatment of hepatoblastomas has been one of the success stories of pediatric oncology. From a disease with a dreadful outlook with survival rates around 35% in the seventies of the last century, survival has now reached over 90% for patients with standard risk tumors, and 45–80% for patients with metastatic disease.3, 4, 5, 6, 7 Progress has been made due to improved surgical technique and better risk stratified chemotherapy based on increasingly refined risk factors. In addition, sharing
Timing of surgery
Over the past two decades the surgical approaches to HB have been different between SIOPEL and the other three major study groups. The SIOPEL group used a single strategy for all patients of delayed surgery following neo-adjuvant chemotherapy in order to make the tumor smaller, less prone to bleed, more demarcated from the surrounding normal hepatic parenchyma and thus more likely to be completely resected by smaller resections.24 In contrast COG, GPOH and JPLT have offered resection at
Hepatocellular carcinoma (HCC)
The incidence of HCC in the western world seems stable or slightly increased.43, 44 In adults, HCC occurs most commonly in the setting of chronic cirrhotic liver disease. In children, however, there are several distinct clinical and biologic patterns of HCC which cluster into two broad categories. First are the sporadic or “de novo” tumors where HCC arises in a normal liver without preceeding liver disease. An ongoing debate questions whether this de novo form of pediatric HCC biologically
Hepatocellular neoplasms-not otherwise specified (HC-NOS), or HB with HCC features
Hepatoblastoma (HB) with hepatocellular carcinoma (HCC) features are a small subset of malignant liver tumors primarily of children in an intermediate age group (5–10 years) that demonstrate features of both HB and HCC, thereby carrying the “transitional tumor” nickname.58 As classically described by Prokurat, the tumor cells themselves may have HCC features.59 Alternatively there may be geographic admixture of histologic patterns with some areas resembling typical HB histology admixed with
Fibrolamellar hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma (FL-HCC) is more common in females and is primarily a tumor of adolescents and young adults. In fact, FL-HCC accounts for about 10–25% of HCC in adolescents and young adults, but only 1% of HCC in adults overall.60, 61, 62, 63, 64 There are no known metabolic diseases which predispose to the development of FL-HCC. In adults FL-HCC is felt to have an improved outcome.63 However, in studies of children this improved survival for FL-HCC was not seen.64, 65
Undifferentiated embryonal sarcoma of the liver (UESL)
UESL is a rare malignant neoplasm of mesenchymal origin,67 recently shown to share genetic features with its benign cousin, mesenchymal harmatoma. Age at diagnosis is usually between 6–10 years but some studies report an older presentation in young teenagers.68 Patients present with abdominal pain and palpable mass, occasionally fever and anorexia with more advanced cases. Because of their internal myxoid nature, imaging may appear centrally cystic and rupture with biopsy attempts is common (
Malignant rhabdoid tumor (MRT) of the liver
Most common in the kidney, the liver is one of several possible primary sites for malignant rhabdoid tumors (MRT) in children. In the kidney it is called rhabdoid tumor of the kidney; in the brain the term is atypical teratoid rhabdoid tumor; and when in the soft tissues or liver as malignant rhabdoid tumor (MRT). MRT can be sporadic or associated with predisposing germline mutations of SMARCB1.85 INI-1 is consistently negative and there is much speculation that before routine testing for
Other malignant tumors involving the liver (nested stromal epithelial, cholangiocarcinoma, hemangioendothelioma, hepatic involvement in hematologic malignancy, liver metastatic disease)
Nested stromal epithelial tumor (NSET) of the liver is a rare neoplasm presenting as a solitary hepatic mass, occurring in childhood and adolescents. Morphologically, the tumor has nests of epithelioid and spindle cells. Some cases have been associated with ectopic ACTH secretion and rarely even may present with Cushing syndrome.88, 89 It has been reported in one child with Beckwith–Wiedemann syndrome.90 Β-catenin mutations (also common in hepatoblastoma) have been reported in two tumors.91
References (105)
- et al.
Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey—1974
J Pediatr Surg
(1975) - et al.
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study
Lancet Oncol
(2013) - et al.
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer
Cancer Cell
(2008) - et al.
Children’s Oncology Group Liver Tumor Committee. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium
Mod Pathol
(2014) - et al.
The genomic landscape of hepatoblastoma and their progenies with HCC-like features
J Hepatol
(2014) Unravelling the genetics of hepatoblastoma: few mutations, what else?
J Hepatol
(2014)- et al.
The Children’s Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model
Eur J Cancer
(2016) - et al.
Association between hepatoblastoma and very low birth weight: a trend or a chance [see comments]?
J Pediatr
(1997) Progress in the surgical treatment of malignant liver tumors in children
Cancer Treat Rev
(2010)- et al.
Guidelines for surgical treatment of hepatoblastoma in the modern era–recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL)
Eur J Cancer
(2005)
Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan
J Hepatol
Hepatocellular carcinoma in children
Clin Liver Dis
Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma
Gastroenterology
Is radioembolization (90Y) better than doxorubicin drug eluting beads (DEBOX) for hepatocellular carcinoma with portal vein thrombosis?
Surg Oncol
The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis
Eur J Cancer
Treatment and prognosis of patiens with fibrolamellar hepatocellular carcinoma: a national perspective
J Am Coll Surg
Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma in children: results and treatment recommendations for the Childhood Liver Tumor Strategy Group (SIOPEL) experience
Eur J Cancer
Non-random p53 mutations in pediatric undifferentiated embryonal sarcoma of the liver
Hepatol Res
Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma
J Pediatr Surg
Hepatobiliary rhabdomyosarcoma mimicking choledochal cyst: lessons learned
Int J Surg Case Rep
Beta-catenin mutations in 2 nested stromal epithelial tumors of the liver—a neoplasia with defective mesenchymal-epithelial transition
Hum Pathol
Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma
J Pediatr
Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints
Cancer Genet
Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals
J Pediatr
Primary non-hodgkins lymphoma of the liver: sonographic and CT findings
Hepatobiliary Pancreat Dis Int
Tumors of the liver
Malignant liver tumors in South African children: a national audit
World J Surg
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
N Engl J Med
Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT
Pediatr Surg Int
Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer
Proc Natl Acad Sci U S A
Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy
Curr Opin Pediatr
The epidemiology of hepatoblastoma
Pediatr Blood Cancer
Liver tumors
Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI: typical, atypical, pre and posttreatment evaluation
Pediatr Radiol
Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the international Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 Study
JCO
2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group
Pediatr Radiol
Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation
Curr Opin Pediatr
The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials
J Indian Assoc Pediatr Surg
New unified global approach to risk stratification and staging in pediatric hepatoblastoma: a report from the Children’s Hepatic tumor International Collaboration (CHIC)
Lancet Oncology
Cisplatin, doxorubicin, and delayed surgery for childhoodhepatoblastoma: a successful approach-results of the first prospective study of the International Society of Pediatric Oncology
J Clin Oncol
Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children’s Oncology Group
J Clin Oncol
Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies
Pediatr Blood Cancer
Successful treatment of childhood high risk hepatoblastoma with dose intensive multiagent chemotherapy and surgery—final results of the SIOPEL-3HR study of the Childhood Liver Tumor Strategy Group
J Clin Oncol
Hepatoblastoma clinical research: lessons learned and future challenges
Pediatr Blood Cancer
Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma
J Clin Oncol
Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience
Pediatr Blood Cancer
Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma
Cancer
Surgical treatment of hepatoblastoma
Pediatr Blood Cancer
Pretreatment prognostic factors in hepatoblastoma: a report of the Children’s Oncology Group
Pediatr Blood Cancer
Cited by (93)
Biology of childhood hepatoblastoma and the search for novel treatments
2024, Advances in Biological RegulationACLY-β-catenin axis modulates hepatoblastoma cell proliferation
2023, Biochemical and Biophysical Research CommunicationsStrategy for hepatoblastoma with major vascular involvement: A guide for surgical decision-making
2023, Surgery (United States)Abdominal and pelvic tumours in children
2022, Surgery (United Kingdom)Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma
2024, Nature CommunicationsEZH2 is a key component of hepatoblastoma tumor cell growth
2024, Pediatric Blood and Cancer